Shree Ganesh Remedies Ltd

Shree Ganesh Rem Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Shree Ganesh Remedies Ltd

₹ 581 0.52%
10 Sep 10:07 a.m.
ganeshremedies.com BSE: 540737
About

Incorporated in 1995, Shree Ganesh Remedies Ltd is a manufacturer of Pharmaceutical Drug Intermediates for API & Fine Chemicals[1]

Key Points

Business Overview:[1]
SGRL is an ISO 14001 certified complex chemical manufacturer, specialising in pharmaceutical intermediates and speciality chemicals.

Website BSE
  • Market Cap ₹ 746 Cr.
  • Current Price ₹ 581
  • High / Low ₹ 950 / 500
  • Stock P/E 34.1
  • Book Value ₹ 113
  • Dividend Yield 0.00 %
  • ROCE 19.2 %
  • ROE 17.0 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2020 Dec 2020 Jun 2021 Sep 2021 Dec 2021 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
11.52 13.26 12.63 16.97 21.13 37.33 24.78 32.33 27.05 24.43 24.67
7.31 10.08 9.58 12.52 15.36 20.39 16.65 21.02 17.14 14.55 17.37
Operating Profit 4.21 3.18 3.05 4.45 5.77 16.94 8.13 11.31 9.91 9.88 7.30
OPM % 36.55% 23.98% 24.15% 26.22% 27.31% 45.38% 32.81% 34.98% 36.64% 40.44% 29.59%
0.45 0.54 1.11 0.44 0.88 1.32 0.54 0.19 0.71 2.29 0.66
Interest 0.01 0.02 0.07 0.03 0.03 0.15 0.32 0.44 0.39 0.97 0.94
Depreciation 0.64 0.22 0.82 0.95 0.99 1.86 2.02 2.42 2.70 2.42 2.42
Profit before tax 4.01 3.48 3.27 3.91 5.63 16.25 6.33 8.64 7.53 8.78 4.60
Tax % 22.94% 20.40% 28.75% 22.76% 25.40% 22.46% 26.70% 25.81% 27.89% 24.83% 25.00%
3.09 2.77 2.34 3.02 4.20 12.59 4.65 6.41 5.42 6.59 3.45
EPS in Rs 2.41 2.16 1.83 2.36 3.28 9.84 3.62 4.99 4.22 5.13 2.69
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2024 Mar 2025 TTM
35 64 49 126 109 108
26 52 35 84 69 70
Operating Profit 9 13 14 42 39 38
OPM % 25% 20% 28% 33% 36% 35%
1 4 2 3 4 4
Interest 0 1 0 1 2 3
Depreciation 1 2 3 6 10 10
Profit before tax 9 14 13 38 31 30
Tax % 28% 23% 25% 26% 26%
6 10 10 28 23 22
EPS in Rs 4.88 8.18 7.62 21.96 17.97 17.03
Dividend Payout % 18% 13% 18% 2% 0%
Compounded Sales Growth
10 Years: %
5 Years: 11%
3 Years: %
TTM: -14%
Compounded Profit Growth
10 Years: %
5 Years: 17%
3 Years: %
TTM: -19%
Stock Price CAGR
10 Years: %
5 Years: 43%
3 Years: 37%
1 Year: -35%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: 17%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2024 Mar 2025
Equity Capital 9 9 13 13
Reserves 25 33 109 132
1 4 36 38
7 9 12 8
Total Liabilities 41 55 171 192
14 20 81 95
CWIP 0 0 17 9
Investments 4 3 5 18
23 32 69 70
Total Assets 41 55 171 192

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2024 Mar 2025
-5 5 3 30 31
-0 -3 -1 -33 -35
-0 -0 -1 10 -1
Net Cash Flow -5 1 2 7 -6

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2024 Mar 2025
Debtor Days 101 101 59 75
Inventory Days 125 61 156 223
Days Payable 75 43 51 61
Cash Conversion Cycle 151 119 164 238
Working Capital Days 145 103 89 111
ROCE % 35% 19%

Shareholding Pattern

Numbers in percentages

Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025
68.27% 68.27% 69.34% 69.34% 69.33% 69.33% 69.33% 69.33% 70.49% 72.80% 72.80% 72.80%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01%
31.73% 31.72% 30.67% 30.66% 30.67% 30.66% 30.67% 30.66% 29.50% 27.19% 27.20% 27.20%
No. of Shareholders 5,8436,4726,7476,4077,3307,5187,0497,1868,5088,6958,9789,166

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Concalls